Provided by Tiger Trade Technology Pte. Ltd.

Teva Pharmaceutical

39.53
+0.22000.56%
Post-market: 39.31-0.2200-0.56%19:30 EDT
Volume:4.77M
Turnover:188.25M
Market Cap:46.05B
PE:65.88
High:39.81
Open:39.31
Low:39.05
Close:39.31
52wk High:40.79
52wk Low:18.83
Shares:1.17B
Float Shares:1.09B
Volume Ratio:0.90
T/O Rate:0.44%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.6000
EPS(LYR):1.21
ROE:9.69%
ROA:5.13%
PB:5.94
PE(LYR):32.67

Loading ...

Teva put volume heavy and directionally bearish

TIPRANKS
·
May 15

Teva, Upstart, Bloom, Corning, Seagate Insider Shock

TIPRANKS
·
May 09

Top Teva Executives Cash Out in Major Insider Stock Moves

TIPRANKS
·
May 08

A Look At Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Strong Q1 2026 And Biopharma Pipeline Progress

Simply Wall St.
·
May 07

Teva Pharmaceuticals Is Maintained at Overweight by Barclays

Dow Jones
·
May 06

Teva Earnings Call Highlights Innovative-Driven Margin Upswing

TIPRANKS
·
May 06

Is It Too Late To Reassess Teva Pharmaceutical Industries (TEVA) After Its Strong Multi Year Rally?

Simply Wall St.
·
May 06

Top Teva Executives Quietly Offload Major Stock Stakes

TIPRANKS
·
May 05

Leader Capital Markets Remains a Buy on Teva (TEVA)

TIPRANKS
·
May 01

Teva Pharmaceuticals Is Maintained at Buy by Truist Securities

Dow Jones
·
Apr 30

Truist Raises Price Target on Teva Pharmaceutical Industries to $45 From $42, Keeps Buy Rating

MT Newswires Live
·
Apr 30

Piper Sandler Reaffirms Their Buy Rating on Teva Pharmaceutical (TEVA)

TIPRANKS
·
Apr 30

A Look At Teva (TEVA) Valuation After Strong Q1 2026 Earnings And Biosimilar Pipeline Progress

Simply Wall St.
·
Apr 30

Teva Upgraded to $45 Price Target on Strong Execution, Emalex Acquisition, and Growing Neurology Pipeline Upside

TIPRANKS
·
Apr 30

Teva price target raised to $45 from $42 at Truist

TIPRANKS
·
Apr 30

Stock Track | Teva Pharmaceutical Soars 12.02% Intraday on Strong Q1 Earnings Beat and Emalex Acquisition

Stock Track
·
Apr 29

Sector Update: Health Care

MT Newswires Live
·
Apr 29

Teva Pharmaceuticals Exec Says Co's Operations Remain Uninterrupted With No Material Impact on 2026 Guidance - Conf Call

THOMSON REUTERS
·
Apr 29

Teva Pharmaceuticals Exec Says It Is Difficult to Predict Whether There Will Be a Channel Drawdown Ahead of Price Changes Set to Take Effect in 2027

THOMSON REUTERS
·
Apr 29

Teva Pharmaceuticals Exec Says Co Is Seeing Nominal Increases in Some Transportation and Energy Costs Related to Middle East Conflict

THOMSON REUTERS
·
Apr 29